Pulmonary Arterial Hypertension (PAH) Market in China 2023
The pulmonary arterial hypertension market in China is projected to rise by USD 913.9 million by 2029, according to the latest market study results. It is anticipated to expand at
- Bonafide Trust
- 22-05-2023
- Region : Asia-Pacific
- Country : China
- Category : Lifescience
- Healthcare
Pulmonary Arterial Hypertension (PAH) is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It occurs when the pulmonary arteries, which carry blood from the heart to the lungs to pick up oxygen, become narrowed and stiff, resulting in increased resistance to blood flow and higher blood pressure in the arteries. PAH can cause symptoms such as shortness of breath, fatigue, chest pain, dizziness, and fainting. It can also lead to complications such as heart failure, blood clots, and infections. The pulmonary arterial hypertension market in China is projected to rise by USD 913.9 million by 2029, according to the latest market study results. It is anticipated to expand at a CAGR of 39.27 percent during the forecast period.
This industry report offers market estimates of the China market, followed by a detailed analysis of the region. The China market data on pulmonary arterial hypertension can be segmented by region: Central South China, East China, North China, Northeast China, Northwest China, Southwest China.
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleThe report also includes the profiles of leading companies such as Actelion Pharmaceuticals Ltd., Bayer AG, Beijing Tide Pharmaceutical Co. Ltd., GlaxoSmithKline plc, United Therapeutics Corporation.
The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.
Why buy this report?
? Get a detailed picture of the China Pulmonary Arterial Hypertension Market
? Identify segments/areas to invest in over the forecast period in the China Pulmonary Arterial Hypertension Market
? Understand the competitive environment, the market’s leading players
? The market estimate for ease of analysis across scenarios in Excel format.
? Strategy consulting and research support for three months.
? Print authentication provided for the single-user license.
Table of Contents
- Part 1. Summary
- Part 2. Introduction
- Study period
- Geographical scope
- Market segmentation
- Part 3. Pulmonary arterial hypertension market overview
- Part 4. Market breakdown by region
- Central South China
- East China
- North China
- Northeast China
- Northwest China
- Southwest China
- Part 5. Key companies
- Actelion Pharmaceuticals Ltd.
- Bayer AG
- Beijing Tide Pharmaceutical Co., Ltd.
- GlaxoSmithKline plc
- United Therapeutics Corporation
- Part 6. Methodology
Related Reports
Allows one individual to access the purchased report Read More
Allows up to five individuals to access the purchased report Read More
Allows all employees of an organization to access the purchased report. Internal sharing only Read More
Allows all employees of an organization to access the purchased report. It also permits the use of up to 4 paragraphs or 1 page of the report externally in whitepapers, press releases, and marketing collateral Read More
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Trusted Partners
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (05 December, 2024)
- Notify To Team (05 December, 2024)
- Report updation (06 December, 2024)
- Report Quality Check (06 December, 2024)
- Report Dispatch (07 December, 2024)
- Hard Copy
Recently Viewed Products
Pulmonary Arterial Hypertension (PAH) Market in China 2023
We are friendly and approachable, give us a call.